Page last updated: 2024-08-17

adenosine diphosphate and pm 01183

adenosine diphosphate has been researched along with pm 01183 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Alfaro, V; Antón, A; Boni, V; Braña, I; Castellano, D; Fernández, C; Huidobro, G; Kahatt, C; Longo, F; Moreno, V; Paredes, A; Pistilli, B; Shapiro, GI; Siguero, M; Subbiah, V; Trigo, J; Zaman, K; Zeaiter, A	1

Trials

1 trial(s) available for adenosine diphosphate and pm 01183

Article	Year
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO open, 2022, Volume: 7, Issue:5 Topics: Adenosine Diphosphate; BRCA1 Protein; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Germ Cells; Germ-Line Mutation; Hormones; Humans; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Ribose	2022

Article

Year

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.

ESMO open, 2022, Volume: 7, Issue:5

Topics: Adenosine Diphosphate; BRCA1 Protein; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Germ Cells; Germ-Line Mutation; Hormones; Humans; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Ribose

2022